Keyphrases
Phase II Study
100%
Response Rate
100%
Partial Response
100%
Southwest Oncology Group
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Renal Cell Carcinoma
100%
Low Response
50%
Thrombocytopenia
50%
Cardiac Toxicity
50%
Phlebitis
50%
Cell Toxicity
50%
Gastrointestinal Side Effects
50%
Dosing Schedule
50%
Alopecia
50%
White Cell
50%
Medicine and Dentistry
Oncology
100%
Clear Cell Renal Cell Carcinoma
100%
Menogaril
100%
Leukocyte
33%
Thrombocytopenia
33%
Cytotoxicity
33%
Gastrointestinal Distress
33%
Drug Dose Regimen
33%
Kidney Cancer
33%
Alopecia Mucinosa
33%
Cardiotoxicity
33%
Phlebitis
33%
Kidney Metastasis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Menogaril
100%
Gastrointestinal Symptom
33%
Cardiotoxicity
33%
Thrombocytopenia
33%
Phlebitis
33%
Kidney Metastasis
33%
Kidney Cancer
33%
Alopecia
33%